Recros Medica develops the Nuvellus® Focal Contouring system to reduce skin laxity and improve focal contouring. The Nuvellus® platform is based on proprietary rotational fractional resection technology and may offer a novel procedure that produces results from a single treatment. The company is also developing Nuvellus® to facilitate autologous dermal transfer as a natural alternative to commercial dermal fillers. Nearly 100 subjects have been treated across four IRB-approved clinical trials, and Recros is planning a pivotal clinical study. Recros is led by president and CEO Tom Albright. The company closed a $14M Series A to continue Nuvellus® development, conduct the pivotal study and pursue FDA clearance to commercialize in the U.S. Recros Medica, co-founded in 2014, is developing a medical aesthetic technology platform called Rotational Fractional Resection with multiple clinical applications. The company is led by President and CEO Tom Albright and was co-founded by Dr. Edward Knowlton and David F. Hale. The platform targets treatment of skin laxity and focal aesthetic contour deformities in the submentum, upper arms, knees and other areas where visible scarring limits traditional plastic surgery. Recros is a development-stage company based in San Diego, CA. It closed a $9M financing to expand its technology platforms in the aesthetics market. The company also strengthened its board with the additions of Christoph Westphal of Longwood Fund and Mark Kerslake of the Province Group.

Total raised

$23M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2019